About Molecular Templates, Inc. - Common Stock (MTEM)
Molecular Templates Inc is a biotechnology company focused on developing innovative therapeutics utilizing its proprietary templated antibody technology. This approach aims to create a new class of targeted therapies that can effectively treat various types of cancer and other serious diseases by harnessing the unique properties of engineered proteins. The company is engaged in extensive research and clinical development to advance its next-generation immunotherapies, striving to enhance efficacy and reduce side effects compared to traditional treatments. Through its commitment to scientific innovation, Molecular Templates is dedicated to improving patient outcomes and transforming the landscape of cancer treatment. Read More
Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. He succeeds Allan Camaisa, who will continue as a Board member. Dr. Poma, a veteran biotech leader, brings over 30 years of experience, including roles at Molecular Templates (NASDAQ: MTEM), where he raised over $250 million and secured strategic partnerships with Takeda, Vertex, and BMS. As Calidi advances its systemic virotherapy platform and prepares for a dose-escalation trial of CLD-201 in solid tumors, the leadership change is expected to support the company’s transition into later-stage clinical development.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.
Molecular Templates shares are trading lower by 77% during Monday's session. The company announced it approved the liquidation and wind-up of the company.
